A NON-INVASIVE, ADAPTIVE DIGITAL THERAPEUTIC SOLUTION FOR POST-TRAUMATIC STRESS...
A NON-INVASIVE, ADAPTIVE DIGITAL THERAPEUTIC SOLUTION FOR POST-TRAUMATIC STRESS DISORDER AND OTHER MENTAL DISORDERS
Post-traumatic stress disorder (PTSD) is a severe mental disorder, annually affecting 3.2% of the population with global market-size estimated at €7.5B. Current treatments’ success is marginal, costly, with severe side-effects. Gr...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BRAINN
BRAIN RESEARCH AND INTEGRATIVE NEUROSCIENCE NETWORK FOR COVI...
1M€
Cerrado
NetworkStim
Evaluation of lesion network mapping as a technique to ident...
158K€
Cerrado
PINGED
Personalizing virtual brains with neurodegenerative disease:...
166K€
Cerrado
TaggingMemory
Understanding whole-brain circuits mediating fear memory att...
265K€
Cerrado
PID2020-119677RB-I00
ASPECTOS BIO-COGNITIVOS MODULABLES Y UN CAMINO HACIA EL BIEN...
97K€
Cerrado
EQC2018-004803-P
Equipo audiovisual de evaluación de la afasia UNCA-CIMES
72K€
Cerrado
Información proyecto GrayMatters for PTSD - GfP
Duración del proyecto: 24 meses
Fecha Inicio: 2022-08-31
Fecha Fin: 2024-08-31
Líder del proyecto
GRAYMATTERS HEALTH LTD
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
4M€
Descripción del proyecto
Post-traumatic stress disorder (PTSD) is a severe mental disorder, annually affecting 3.2% of the population with global market-size estimated at €7.5B. Current treatments’ success is marginal, costly, with severe side-effects. GrayMatters is the first to introduce a non-invasive
digital-therapeutics device harnessing brain plasticity to help PTSD patients control abnormal brain-region activity. Our patented innovation uses machine-learning to convert EEG signal to an fMRI-like signal of the amygdala such that patients learn to self-control their amygdala activity
level using affordable EEG-Neurofeedback device. Initial clinical-trials on stress-resilience & PTSD patients showed significant positive clinical results. The founders have 25+ years experience in commercialization, healthcare & technology with several startups exits/IPOs. LOIs
includes top mental-institutes and world-renowned KOLs of PTSD psychiatry. GMH was recently chosen as 1 of 8 innovative companies by Nature magazine.